読み込み中
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
前日終値
$13.19
+$0.365 · +2.85%
日中の時刻はETです。市場データは遅延する場合があります。
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
日中レンジ
現在 $13.19
52週レンジ
現在 $13.19
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
57
まちまち
リスク
45
やや高いリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
日中レンジ
現在 $13.19
52週レンジ
現在 $13.19
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 3347.8万 USD | 3937.7万 USD | 2368.3万 USD | 1983.4万 USD | 2298.4万 USD |
| 販売・一般管理 | 1585万 USD | 1214.7万 USD | 1024万 USD | 1007.3万 USD | 949.2万 USD |
| 営業費用 | 4932.8万 USD | 5152.4万 USD | 3392.3万 USD | 2990.7万 USD | 3247.6万 USD |
| 受取利息 | 653.6万 USD | 360.2万 USD | 474.8万 USD | 174万 USD | 1万 USD |
| 支払利息 | — | 4000 USD | 39.1万 USD | 78万 USD | 120.2万 USD |
| 減価償却費と償却費 | 14.4万 USD | 14.7万 USD | 12.3万 USD | 4.3万 USD | 5万 USD |
| 営業利益 | −4932.8万 USD | −5152.4万 USD | −3392.3万 USD | −2990.7万 USD | −3247.6万 USD |
| 純利益 | −4275.9万 USD | −4791.1万 USD | −2906.5万 USD | −2915.2万 USD | −3394万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$29.67
上昇余地（124.94%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI6739.32万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3677.09万0.05%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2269.39万0.02%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1298.71万0.09%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO1022.62万0.06%180億 USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB957.84万0.09%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA814.19万0.04%218.24億 USD0.03%$32.79+0.40%
State Street SPDR S&P Pharmaceuticals ETFXPH722.84万1.57%4.62億 USD0.35%$64.65+1.60%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAState Street SPDR S&P Pharmaceuticals ETFXPHAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
